A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma. This is an ...

The Food and Drug Administration (FDA) has approved the combination of pembrolizumab (Keytruda, Merck Sharp & Dohme) with lenvatinib (Lenvima, Eisai Inc) for the first-line treatment of adult patients ...

Combining lenvatinib (Lenvima) with an immune checkpoint inhibitor in the first-line setting for unresectable hepatocellular carcinoma (HCC) failed to significantly improve survival outcomes in an ...

The study covered in this summary was published on Research Square as a preprint and has not yet been peer reviewed. Anaplastic thyroid cancer is a rare thyroid malignancy; disease-specific mortality ...

Combining transarterial chemoembolization (TACE) with lenvatinib (Lenvima) as first-line treatment for advanced hepatocellular carcinoma (HCC) prolonged survival compared with lenvatinib alone, the ...

Please provide your email address to receive an email when new articles are posted on . Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with ...

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ®) in ...

Merck and Eisai announced disappointing results from 2 clinical trials evaluating pembrolizumab (Keytruda ®) with lenvatinib (Lenvima ®). According to the Companies, the phase 2 LEAP-003 trial ...

At about 4 years of follow-up, first-line treatment with lenvatinib and pembrolizumab continued to confer a benefit over sunitinib monotherapy in patients with advanced renal cell carcinoma. Updated ...

X-ray of human kidneys. It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term. Compared with sunitinib, the combination of ...

Learn everything you need to know about Lenvatinib-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

With a deadline of April 14, the FDA will soon make its final approval decision on lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid ...